Actual - Real Estate

As markets are decelerating, there is an anxious face-off between sellers and buyers of real capital assets as expectations of big profits fade away just as well.

In economic terms, the slowdown that we

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

are witnessing today in many real estate markets is actually welcome news since allowing the economy to cool off through a reversal of real capital appreciation while at the same time allowing real wages to catch up is

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

xactly the tonic needed to consolidate market wealth achieved thus far, eliminate the 'froth' by reducing speculation and, in ultimate analysis, keep bubbles away.

But then, of course, not all of us are economists - at

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

least not my own clients.

The house party had to end eventually, even if many sellers still refuse to believe it. In fact many sellers remain defiant to the point of delusion, demanding one more drink at the housing bar

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

‘Stickiness' is a noun used in Economics to describe a situation in which a variable is resistant to change. Price stickiness, therefore, reflects the fact that asking prices of interests in land remain high and e

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

ven increase at a time when demand lowers.

Sales of existing homes, both new and resale, are down 7 percent and 6.6 percent nationwide respectively in the United States and Canada in the first quarter of 2007 compared t

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

one year ago. Buyers are taking their time, leery of overpaying and taking on too much debt, and yet particularly in the United States the National Association of Realtors reports that in the first quarter of this year

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

listing prices of single-family detached units not only failed to match the decline in demand, but in fact in eighty-two metropolitan areas they actually increased compared to a year ago.

Experts in market psychology sa

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

stubborn sellers suffer of a classic case of denial. When it comes to financial-making behaviour, people would rather gamble and hope that prices come back. They tend to ignore information suggesting that prices are dro

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

pping. It is the same mentality that leads blackjack players to double down in a losing streak. This explains sellers' reluctance to cut down prices, and in fact several academic studies also suggest that frustrated sell

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

rs take their homes off the market rather than accepting lowball offers. Conversely, when investors see prices rise they get overconfident - much like the hot-hand bias that leads folks to think a basketball player will

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

ink his fourth shot after making the prior three, even though probability says the odds are the same for every shot.

Price stability certainly is the utmost desire of central bankers, in any market. In fact, many a cent

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

ral bank have it, more or less. Consumer-price inflation hovers to 2 percent in America, 2.2 percent in Canada, 1.6 percent in the Euro Zone and 0.6 percent in Japan. One might argue, therefore, that because the overall

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

rice level is not changing a lot, nor are individual prices - but this is not necessarily a rule of thumb.

How often prices move is an important question. Shifts in prices are like the traffic lights of an economy, sign

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

alling to people to buy more of this and less of that, to spend or to save, or to find new jobs. If the lights change readily, resources can be redirected smoothly. If they get stuck, so does the economy. In particular,

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

f neither prices nor wages shift easily, the cost in output and jobs and, ultimately, the cost of reducing inflation can be high. Sticky prices also mean that an inflationary shock - an increase in oil prices, for instan

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ce, like the one that is happening this very moment - can take a long time to work its way through the system.

Price stickiness in any market, but especially in a big-ticket market such as Real Estate, is responsible fo

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

and reflects some confusion that exists between nominal and real values and gives rise, moreover, to a particular phenomenon known as the ‘Money Illusion'. Money illusion does influence people perceptions of outco

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

mes. Experiments have shown that people generally perceive a 2 percent cut in nominal income as unfair, but see a 2 percent rise in nominal income where there is 4 percent inflation as fair, despite the fact that the two

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

situations are almost rational equivalents. The same happens in Real Estate, where the trend is for asking prices to remain high or even increase when selling prices are dropping.

Luigi Frascati

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

Tags

Links

Actual - Sticky Deals

Related Articles: